Einsatz oraler Antidiabetika in der Therapie des Kinderwunsches, des Gestationsdiabetes und zur Prävention des Typ-2-Diabetes

Zusammenfassung

Die Therapie des polyzystischen Ovarsyndroms (PCOS) hat in der vergangenen Zeit neue Impulse durch den Einsatz oraler Antidiabetika (OAD) erhalten. Der Übersichtsbeitrag gibt einen Einblick in die aktuelle Studienlage hinsichtlich des Einsatzes verschiedener OAD bei Kinderwunsch. Weiterer Schwerpunkt dieses Beitrages ist der Einsatz von OAD während der Schwangerschaft sowie post partum. Dabei wird auch auf den klinischen Wert einer Hyperinsulinämie eingegangen.

Abstract

The therapy of polycystic ovarian syndrome has changed considerably in recent years due to the use of oral antidiabetics (OAD). This review gives an overview of the present indications for different OAD in fertility treatment. The use during pregnancy and post partum and the significance of hyperinsulinaemia in this context is evaluated critically.

Schlüsselwörter

Orale Antidiabetika - Schwangerschaft - Gestationsdiabetes - Typ-2-Diabetes-mellitus - Hyperinsulinämie

Key words

Oral antidiabetics - pregnancy - gestational diabetes - type-2 diabetes - hyperinsulinaemia

Literatur

• 1 Knick B, Schwarz P, Schernthaner G. et al .Metformin. Mehnert H et al. Metformin in der Diabetestherapie. Bremen; Uni-Med 2004
• 2 Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman M F, Goodyear L J, Moller D E. Role of AMP-activated protein kinase in mechanism of metformin action.  J Clin Invest. 2001;  108 1167-1174
• 3 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
• 4 Lord J M, Flight I H, Norman R J. Metformin in polycystic ovary syndrome: systematic review and meta-analysis.  BMJ. 2003;  327 951-953
• 5 Lord J M, Flight I H, Norman R J. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome.  Cochrane Database Syst Rev. 2003;  3 CD003053
• 6 Nestler J E, Jakubowicz D J, Evans W S, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.  N Engl J Med. 1998;  338 1876-1880
• 7 Fleming R, Hopkinson Z E, Wallace A M, Greer I A, Sattar N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab.  . 2002;  87 569-574
• 8 George S S, George K, Irwin C, Job V, Selvakumar R, Jeyaseelan V, Seshadri M S. Sequential treatment of metformin and clomiphene citrate in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial.  Hum Reprod. 2003;  18 299-304
• 9 Kjotrod S B, von During V, Carlsen S M. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study.  Hum Reprod. 2004;  19 1315-1322
• 10 Glueck C J, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.  Fertil Steril. 2001;  75 46-52
• 11 Jakubowicz S, Roberts K A, Nestler J E, Jakubowicz D J, Iuorno M J. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2002;  87 524-529
• 12 McCarthy E A, Walker S P, McLachlan K, Boyle J, Permezel M. Metformin in obstetric and gynecologic practice: a review.  Obstet Gynecol Surv. 2004;  59 118-127
• 13 Glueck C J, Wang P, Kobayashi S, Phillips H, Sieve-Smith L. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.  Fertil Steril. 2002;  77 520-525
• 14 Langer O, Conway D L, Berkus M D, Xenakis E M, Gonzales O. A comparison of glyburide and insulin in women with gestational diabetes mellitus.  N Engl J Med. 2000;  343 1134-1138
• 15 Jacobson G F, Ramos G A, Ching J Y, Kirby R S, Ferrara A, Field D R. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization.  Am J Obstet Gynecol. 2005;  193 118-124
• 16 Azziz R, Ehrmann D, Legro R S, Whitcomb R W, Hanley R, Fereshetian A G, O'Keefe M, Ghazziy M N. PCOS/Troglitazone Study Group . Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.  J Clin Endocrinol Metab. 2001;  86 1626-1632
• 17 Buchanan T A, Xiang A H, Peters R K, Kjos S L, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz K, Hodis H N, Azen S P. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women.  Diabetes. 2002;  51 2796-2803
• 18 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
• 19 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1999;  352 837-853 Lancet. 1999;  354 602
• 20 Diabetes Prevention Program Research Group . Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 21 Ruige J B, Assendelft W J, Dekker J M, Kostense P J, Heine R J, Bouter L M. Insulin and risk of cardiovascular disease: a meta-analysis.  Circulation. 1998;  97 996-1001
• 22 Pyorala M, Miettinen H, Laakso M, Pyorala K. Hyperinsulinemia and the risk of stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study.  Stroke. 1998;  29 1860-1866
• 23 Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens E J, Pyorala K. DECODE Insulin Study Group . Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies.  Diabetologia. 2004;  47 1245-1256
• 24 Tuomilehto J, Lindstrom J, Eriksson J G, Valle T T, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M. Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
• 25 Berger M, Mühlhauser I. Surrogat-Marker: Trugschlüsse.  Dt Ärztebl. 1996;  49 A-3280